Related Experiment Video
Updated: Mar 24, 2026
Author Spotlight: Photodynamic Therapy as a Novel Approach to Induce Petite Colonies in Drug-Resistant Candida for Antifungal Research
Published on: March 29, 2024
A rash diagnosis: Gemcitabine-associated pseudocellulitis
Christopher Strouse1, Narendranath Epperla2
11 Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract:
Gemcitabine is an antitumor agent with broad clinical application. The most common cutaneous toxicities are mild rash and pruritus; however, a severe 'pseudocellulitis' rash, which resembles infectious cellulitis in clinical presentation, has increasingly been recognized as a rare complication of this agent. Though the specific pathophysiology related to this condition is not clear, it has been observed to occur primarily in regions of significant lymphadenopathy or prior radiation exposure typically after 24-48 h following administration of gemcitabine. It is a self-limiting reaction, with most cases resolving within two to seven days of onset without any specific treatment for the rash. Treatment with gemcitabine may be safely continued in patients with this complication, though recurrence of the rash is common following repeated doses. We report a case of biopsy confirmed gemcitabine associated pseudocellulitis in a patient treated for metastatic pancreatic adenocarcinoma. Knowledge of this complication is important to avoid unwarranted hospitalizations and antibiotic use in patients treated with gemcitabine.
Insights
Gemcitabine can cause a rare but severe skin reaction called pseudocellulitis. This condition mimics infection but is self-limiting, allowing continued gemcitabine treatment.
Area of Science:
- Oncology
- Dermatology
- Clinical Pharmacology
Background:
- Gemcitabine is a widely used chemotherapy drug.
- Cutaneous toxicities, including rash and pruritus, are common side effects.
- A severe 'pseudocellulitis' rash, mimicking infectious cellulitis, is a recognized rare complication.
Purpose of the Study:
- To report a case of biopsy-confirmed gemcitabine-associated pseudocellulitis.
- To highlight the clinical presentation and management of this rare adverse event.
- To emphasize the importance of recognizing this complication to prevent unnecessary interventions.
Main Methods:
- Case report of a patient with metastatic pancreatic adenocarcinoma treated with gemcitabine.
- Clinical observation of a severe rash resembling cellulitis.
- Biopsy confirmation of the pseudocellulitis reaction.
- Review of literature regarding gemcitabine-induced pseudocellulitis.
Main Results:
- The patient developed a severe rash consistent with pseudocellulitis after gemcitabine administration.
- The reaction was biopsy-confirmed and occurred in the context of lymphadenopathy.
- The rash was self-limiting, resolving within days without specific treatment.
- Gemcitabine treatment was continued safely, despite the recurrence of the rash upon subsequent doses.
Conclusions:
- Gemcitabine-associated pseudocellulitis is a rare but important dermatologic complication.
- Prompt recognition can prevent misdiagnosis as infectious cellulitis, avoiding unnecessary antibiotics and hospitalization.
- This condition is typically self-limiting, and gemcitabine therapy can often be safely continued.